TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31375051
Drug: Dasotraline 4
Normalized name: Dasotraline
DrugBank: Dasotraline (DB12305)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasotraline 4 mg
Study: 25762165
Drug: Duloxetine 20
Normalized name: duloxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 20 mg/day for 1 week, then 40 mg/day for 3 weeks
Study: 25762165
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 (VB12) 1.5 mg/day for 4 weeks
Study: 21469249
Drug: Medicamental therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicamental therapy (Control)
Study: 16309929
Drug: Therapeutic education
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic education and functional readaptation (TEFR) added to conventional (pharmacological) treatment (n=51)
Study: 16309929
Drug: Conventional (pharmacological)
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional (pharmacological) treatment only (n=49)
Study: 11301848
Drug: Gemcitabine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine and cisplatin as induction therapy followed by concomitant chemoradiation
Study: 11301848
Drug: Cisplatin-based combinations
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based combinations (with gemcitabine, paclitaxel, or vinorelbine) as induction therapy
Study: 8424584
Drug: Low-dose polyunsaturated
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose polyunsaturated fatty acids from fish oil (350 mg daily) in microencapsulated form
Study: 8424584
Drug: Low-dose polyunsaturated
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose polyunsaturated fatty acids from fish oil (350 mg daily) in gelatine capsules
Study: 8424584
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations of fish oil
Study: 27444039
Drug: Atomoxetine oral
Normalized name: atomoxetine Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine oral solution 50 mg
Study: 27444039
Drug: Atomoxetine capsules
Normalized name: Atomoxetine Capsules
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomoxetine capsules 50 mg
Study: 27444039
Drug: Atomoxetine oral
Normalized name: atomoxetine Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine oral solution
Study: 16150136
Drug: phe-free protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: phe-free protein substitute supplemented with EFA (test-treatment group)
Study: 10388983
Drug: Macroalbuminuric subjects
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macroalbuminuric subjects (AER = 300 mg/day)
Study: 8637536
Drug: Co-trimoxazole (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (800 mg of sulfamethoxazole and 160 mg of trimethoprim) given twice daily for 24 months
Study: 6472539
Drug: L-carnitine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (3 g/day)
Study: 31829921
Drug: 5% Date
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% Date Palm Kernel Extract (DPKE) cream applied twice daily for 8 weeks
Study: 18187428
Drug: PGA (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGA (60 mg)
Study: 15890731
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (cetrorelix 0.25 mg daily starting when the leading follicle reached 14 mm)
Study: 12626212
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (HRT) using a combination of transdermal estradiol gel and a progestin other than MPA
Study: 8208872
Drug: Galanthamine 10
Normalized name: Galanthamine
DrugBank: Galantamine (DB00674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Galanthamine 10 mg
Study: 8208872
Drug: Galanthamine 15
Normalized name: Galanthamine
DrugBank: Galantamine (DB00674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Galanthamine 15 mg
Study: 2563217
Drug: Oral potassium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral potassium pretreatment
Study: 1164890
Drug: Sisomicin (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sisomicin (1.0 mg/kg body-weight, 2-3 times daily)
Study: 1164890
Drug: Gentamicin (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin (1.0 mg/kg body-weight, 1-hour infusion)
Study: 1164890
Drug: Sisomicin (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sisomicin (1.0 mg/kg body-weight, 1-hour infusion)
Study: 1164890
Drug: Tobramycin (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin (1.0 mg/kg body-weight, 1-hour infusion)
Study: 30616534
Drug: Axitinib titration
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Axitinib titration (5 mg bid)
Study: 23651793
Drug: 1 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 × 30 mg/mL subcutaneous injection
Study: 23651793
Drug: 2 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 × 15 mg/mL subcutaneous injections
Study: 21060995
Drug: BZP/TFMPP (100/30
Approvals — FDA: no, EMA: no, PMDA: no
Description: BZP/TFMPP (100/30 mg)
Study: 17308499
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg soy-derived isoflavones
Study: 15183623
Drug: Compression treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression treatment with superficial venous surgery
Study: 21345766
Drug: Compression treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression treatment alone
Study: 820708
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of synthetic TRH three times a day, 30 minutes before breast feeding
Study: 29446785
Drug: Salso-bromo-iodine thermal
Normalized name: 2-bromo-2-methylpropane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salso-bromo-iodine thermal water solution administered by nasal douche twice/day for 10 days a month for 3 months
Study: 29446785
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline administered by nasal douche twice/day for 10 days a month for 3 months
Study: 17413915
Drug: Placebo FICB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo FICB with 0.9% saline and intramuscular injection of 0.1 mg/kg morphine
Study: 11849632
Drug: Contraceptive patch
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive patch (Ortho Evra/Evra)
Study: 10492057
Drug: Caffeine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (300 mg) administered during the ovulatory phase (days 13-16 post-onset of menses)
Study: 10492057
Drug: Caffeine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (300 mg) administered during the luteal phase (days 22-26 post-onset of menses)
Study: 10492057
Drug: Caffeine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (300 mg) administered during the follicular phase (days 2-6 post-onset of menses)
Study: 28035542
Drug: CZSG (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: CZSG (12 mg orally, thrice daily)
Study: 28035542
Drug: KFX (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: KFX (10 mL orally, thrice daily)
Study: 22382664
Drug: low-DEX (loading,
Approvals — FDA: no, EMA: no, PMDA: no
Description: low-DEX (loading, 3 μg/kg/h for 10 min; maintenance, 0.2 μg/kg/h for 60 min)
Study: 22382664
Drug: moderate-DEX (loading,
Approvals — FDA: no, EMA: no, PMDA: no
Description: moderate-DEX (loading, 6 μg/kg/h for 10 min; maintenance, 0.4 μg/kg/h for 60 min)
Study: 17590198
Drug: Topical mometasone
Normalized name: mometasone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical mometasone furoate 0.1%
Study: 15731121
Drug: Topical tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tacrolimus 0.1%
Study: 9618736
Drug: Cotrimoxazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotrimoxazole (100 mg/kg b.w./24 h)
Study: 2116316
Drug: Almitrine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine (100 mg oral)
Study: 6995131
Drug: Clofibate 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofibate 0.5 g
Study: 6995131
Drug: Bezafibrate 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate 0.2 g
Study: 20021927
Drug: tirofiban (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: tirofiban (intravenous bolus 10 microg/kg followed by intravenous infusion of 0.15 microg/kg/min for 48 h)
Study: 9871425
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg quinidine premedication
Study: 7608829
Drug: L. casei
Normalized name: L. casei
DrugBank: Lactobacillus casei (DB16541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. casei subsp. rhamnosus (Lactophilus)
Study: 7608829
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Streptococcus thermophilus and L. delbrückii subsp. bulgaricus (Yalacta)
Study: 2571860
Drug: CD45 monoclonal
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD45 monoclonal antibodies (mAbs) perfusion
Study: 2571860
Drug: Control human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control human albumin solution
Study: 371293
Drug: Oral cholera
Normalized name: VIBRIO CHOLERAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cholera chemical vaccine (2 tablets)
Study: 371293
Drug: Oral cholera
Normalized name: VIBRIO CHOLERAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cholera chemical vaccine (3 tablets)
Study: 31434149
Drug: six-dose IV-TXA
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: six-dose IV-TXA (total dosage more than 6 g)
Study: 22507386
Drug: Bifidobacterium bifidum
Normalized name: Bifidobacterium Bifidum
DrugBank: Bifidobacterium bifidum (DB16538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium bifidum OLB6378 (B. bifidum) administered within 48 hours of birth
Study: 22507386
Drug: Bifidobacterium bifidum
Normalized name: Bifidobacterium Bifidum
DrugBank: Bifidobacterium bifidum (DB16538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium bifidum OLB6378 (B. bifidum) administered more than 48 hours after birth
Study: 20674669
Drug: Biologic agents
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic agents for treatment of rheumatic diseases
Study: 17659971
Drug: Topical moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical moxifloxacin 0.5% every 10 minutes for one hour before surgery
Study: 17659971
Drug: Topical ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ofloxacin 0.3% every 10 minutes for one hour before surgery
Study: 10201739
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids pretreatment
Study: 2118853
Drug: rt-PA 100
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rt-PA 100 mg (29.6-48.2 MU) administered over 90 min followed by intravenous heparin
Study: 30382900
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment without 3D image fusion guidance
Study: 20074202
Drug: Adherence therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence therapy intervention
Study: 20074202
Drug: Medication management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication management training for mental health nurses
Study: 17342036
Drug: Dobutamine stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine stress echocardiography in small-size AVR group (n=17) with prosthetic aortic valves 21 mm; Peak pressure gradient at rest: 42.1 mm Hg, after dobutamine infusion: 85.1 mm Hg (P<0.05). Isovolumetric relaxation time returned to normal, significant decrease in left atrium and left ventricular diameters and volumes, LVMI decreased from 127.6±47.6 to 98.1±36.9.
Study: 17342036
Drug: Dobutamine stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine stress echocardiography in large-size AVR group (n=13) with valves >21 mm; Peak pressure gradient at rest: 20.9 mm Hg, after dobutamine infusion: 54 mm Hg (P<0.05). LVMI decreased from 159.9±16.1 to 125.3±10.1.
Study: 11547472
Drug: Intrathecal 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal 0.3 mg morphine plus intravenous saline (group 1)
Study: 11547472
Drug: Intravenous 0.09
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 0.09 mg buprenorphine plus intrathecal saline (group 2)
Study: 11547472
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 0.3 mg plus intravenous buprenorphine 0.09 mg (group 3)
Study: 3045264
Drug: Melphalan (arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melphalan (arm B) 8 mg/m2/d X 4 every 4 weeks X 18 courses (106 patients)
Study: 29079949
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (Control, n=53)
Study: 19738125
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg/d) with gemcitabine (1,250 mg/m² days 1 and 8) and cisplatin (75 mg/m² day 1) or carboplatin (5 x AUC, day 1)
Study: 19738125
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with gemcitabine (1,250 mg/m² days 1 and 8) and cisplatin (75 mg/m² day 1) or carboplatin (5 x AUC, day 1)
Study: 15019365
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of 4 mg of triamcinolone acetonide
Study: 11082826
Drug: 0‐mg nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0‐mg nicotine gum (placebo)
Study: 2453596
Drug: Pyrazinamide (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrazinamide (1500 mg for 2 months)
Study: 26872868
Drug: Traditional protocol
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional protocol (iopromide 370 mg/mL + 120 kV)
Study: 26872868
Drug: Low tube
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tube voltage (100 kV), low contrast agent concentration (270 mg/mL), and iterative reconstruction
Study: 24330619
Drug: Cranberry beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry beverage (450 ml daily for 10 weeks)
Study: 16361302
Drug: Gabapentin (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (1.2 g day(‐1))
Study: 320830
Drug: Pipamperone (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pipamperone (80 mg daily)
Study: 7151088
Drug: Intravenous tiapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tiapamil (1 mg/kg loading dose followed by 50 micrograms/kg/min infusion for 15 min)
Study: 7151088
Drug: Intravenous tiapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tiapamil (1.5 mg/kg loading dose followed by 75 micrograms/kg/min infusion for 15 min)
Study: 27102891
Drug: Pancreatic enzyme
Normalized name: Pancreatic enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatic enzyme replacement therapy (PERT) administered 10 minutes before a meal
Study: 27102891
Drug: Pancreatic enzyme
Normalized name: Pancreatic enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatic enzyme replacement therapy (PERT) administered 10 minutes after a meal
Study: 22260713
Drug: Running therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Running therapy (RT) or Nordic walking (NW) in addition to usual care, group-based, 1 hour session, two times a week for 6 months, increasing intensity.
Study: 17983307
Drug: Daily event
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily event sampling study; Study 3
Study: 9817265
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (six cycles of cyclophosphamide, methotrexate, fluorouracil, and prednisone)
Study: 9817265
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment (observation group)
Study: 9817265
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (for patients with large tumors, both ER+ and ER-)
Study: 9817265
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment (observation group for patients with large tumors, both ER+ and ER-)
Study: 9817265
Drug: Low-risk patients
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-risk patients (ER+ tumors < 3 cm) monitored without therapy
Study: 2664631
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 12 interrupted 10‐0 sutures with a single running 11‐0 suture (IR)
Study: 765528
Drug: Metaproterenol syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metaproterenol syrup
Study: 25452437
Drug: Exercise (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise (150 minutes per week of aerobic exercise and supervised strength training twice per week)
Study: 11848115
Drug: Auditory, tactile,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auditory, tactile, visual, and vestibular intervention (ATVV) administered for 15 minutes, twice daily, 5 days per week, from 33 weeks of age until discharge.
Study: 8597883
Drug: Indomethacin, diclofenac,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin, diclofenac, and naproxen (nonsteroidal anti-inflammatory drugs)
Study: 2693074
Drug: maprotiline 75
Normalized name: maprotiline 75 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: maprotiline 75 mg
Study: 2693074
Drug: maprotiline 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: maprotiline 37.5 mg (1/2 tablet)
Study: 2693074
Drug: placebo 1
Normalized name: placebo 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 1 tablet
Study: 2693074
Drug: placebo 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 37.5 mg (1/2 tablet)
Study: 352195
Drug: RO 21‐3981
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO 21‐3981 0.15 mg/kg
Study: 30885233
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of antidepressants
Study: 30885233
Drug: HDL-cholesterol levels
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDL-cholesterol levels (per mmol/l)
Study: 26747218
Drug: Bag-valve-mask +
Normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bag-valve-mask + nasal cannula at 10 L/min
Study: 26747218
Drug: Nonrebreather face
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonrebreather face mask + nasal cannula at 10 L/min
Study: 23156974
Drug: Midazolam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (2 mg/kg)
Study: 23156974
Drug: Flumazenil (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.05 mg/kg)
Study: 19528136
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (2 years of one agent followed by 3 years of the other)
Study: 17340069
Drug: Wobe-Mugos E
Normalized name: pine needle oil (pinus mugo)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wobe-Mugos E (proteolytic enzymes) comprising papain 100 mg, trypsin 40 mg, and chymotrypsin 40 mg
Study: 15206666
Drug: Sustained-release (SR)
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release (SR) low-dose isradipine (15 mg)
Study: 15206666
Drug: Sustained-release (SR)
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release (SR) high-dose isradipine (30 mg)
Study: 15206666
Drug: Low-dose cocaine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cocaine HCl (0.325 mg/kg)
Study: 15206666
Drug: High-dose cocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cocaine HCl (0.650 mg/kg)
Study: 3117399
Drug: Sequential instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential instillation of mitomycin C (MMC) and adriamycin (ADM); 20 mg MMC on day 1 and 40 mg ADM on day 2, repeated weekly for 5 weeks.
Study: 3117399
Drug: 5‐fluorouracil (5‐FU)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐fluorouracil (5‐FU) medication
Study: 26347218
Drug: α-lipoic acid
Normalized name: α-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-lipoic acid (ALA) treatment (600mg once daily)
Study: 22822623
Drug: N. sativa
Approvals — FDA: no, EMA: no, PMDA: no
Description: N. sativa capsules (500 +/- 10 mg per capsule, 2 g per day for 4 weeks)
Study: 18441041
Drug: Sensorimotor training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensorimotor training programme using a sling suspension system
Study: 18441041
Drug: Routine physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine physical therapy (Control)
Study: 12556017
Drug: 150 ml
Normalized name: REBYOTA 150 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 ml paper disposable cup
Study: 3158187
Drug: Diltiazem, 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem, 90 mg three times a day by mouth for 3 months after PTCA
Study: 3158187
Drug: Calcium antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonists discontinued immediately after PTCA (Control)
Study: 29996492
Drug: IF 1
Normalized name: SAIF 1 Micro
Approvals — FDA: no, EMA: no, PMDA: no
Description: IF 1 (1.0 g protein/dL)
Study: 29996492
Drug: IF 2
Normalized name: GILOTRIF 20mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: IF 2 (1.3 g protein/dL)
Study: 29996492
Drug: IF 3
Normalized name: GILOTRIF 30mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: IF 3 (1.5 g protein/dL)
Study: 26201313
Drug: Weekly adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly adalimumab
Study: 26337327
Drug: Clinician feedback
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician feedback group (received feedback weekly)